Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...
Nasdaq16d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
The phase IIb study is evaluating batoclimab in CIDP patients whose disease had worsened during standard-of-care treatment. CIDP is a rare autoimmune neurological disorder that causes progressive ...
Nasdaq18d
Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results for Batoclimab in MG and Phase 2b Study in CIDP
The lack of detailed data or outcomes from the Phase 3 study of batoclimab in MG and the Phase 2b study in CIDP prior to the webcast may raise concerns among investors about the effectiveness of ...
Queen's University19d
Crisis in Sudan
Since April 2023, the Sudanese Armed Forces (SAF) and the paramilitary Rapid Support Forces (RSF) have been engaged in a civil war rife with human rights violations and attacks on civilian ...
Opinion
The urgent need for better treatments for Guillain-Barré Syndrome
Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome. That's welcome news.
rarediseaseadvisor29d
Understanding Site-Specific Pathophysiology of CIDP
The presence of unique T-cell clones in nerve tissue might indicate that CIDP’s immune response is more localized than previously thought. The immune response involved in chronic inflammatory ...